Table 3.

Treatment comparison of continued thienopyridine vs. placebo in randomized subjects with vs. without anatomical complexity, according to intention-to-treat analysis with subjects who had anatomic lesion complexity information available.

Event	Continued Thienopyridine (N=5812)	Placebo (N=5742)	Hazard Ratio [95% CI]	Risk Difference [95% CI] Continued Thienopyridine - Placebo	Log Rank P-value	P Value for Risk Difference	P Value for Interaction
MI or Stent thrombosis						0.75	0.81
Complex (N=3730)	46 (2.5%)	81 (4.5%)	0.55 [0.38, 0.79]	−2.0% [−3.2%,−0.8%]	0.001
Not Complex (N=7824)	76 (2.0%)	143 (3.8%)	0.52 [0.39, 0.69]	−1.8% [−2.5%,−1.0%]	<.001
MACCE						0.71	0.88
Complex (N=3730)	85 (4.7%)	114 (6.3%)	0.72 [0.55, 0.96]	−1.7% [−3.2%,−0.2%]	0.02
Not Complex (N=7824)	157 (4.1%)	207 (5.5%)	0.74 [0.60, 0.91]	−1.4% [−2.3%,−0.4%]	0.01
Bleeding (moderate/severe)						0.41	0.44
Complex (N=3730)	40 (2.2%)	28 (1.6%)	1.41 [0.87, 2.28]	0.6% [−0.3%,1.5%]	0.16
Not Complex (N=7824)	93 (2.5%)	52 (1.4%)	1.78 [1.27, 2.50]	1.1% [0.4%,1.7%]	<.001